TrialGynecologic oncology2017

Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

David E Cohn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.